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Abstract
Lung cancer being the most prevalent malignancy in men and the 3rd most frequent in women is still
associated with dismal prognosis due to advanced disease at the time of diagnosis. Novel targeted
therapies are already on the market and several others are under investigation. However
non-specific cytotoxic agents still remain the cornerstone of treatment for many patients. Central
airways stenosis or obstruction may often complicate and decrease quality of life and survival of
these patients. Interventional pulmonology modalities (mainly debulking and stent placement) can
alleviate symptoms related to airways stenosis and improve the quality of life of patients. Mitomycin C and sirolimus have been observed to assist a successful stent placement by reducing
granuloma tissue formation. Additionally, these drugs enhance the normal tissue ability against
cancer cell infiltration. In this mini review we will concentrate on mitomycin C and sirolimus and
their use in stent placement.
Key words: pharmacology, stents.

Introduction
Lung cancer still remains a difficult to treat cancer, since patients are diagnosed at late stage disease
due to lack of symptoms.[1] Moreover; lung cancer is
the second most lethal cancer after prostate for men
and breast for women, with a trend to increase for
women in the future.[1] Several medical societies are
trying to identify those groups of patients that will
benefit from imaging screening with several novel

techniques.[2-4] Until now there is no algorithm for
early diagnostic approach for lung cancer, and patients are usually investigated if symptoms appear. In
the last decade several molecular pathways have been
investigated and several novel drugs are already on
the market for non-small cell lung cancer
(NSCLC).[5-8] Regarding small cell lung cancer
(SCLC) we still do not have novel therapies, however;
http://www.jcancer.org
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novel treatment approaches are investigated with the
main concept of immunomodulation being the most
feasible right now.[9-14] Side effects from non-specific
cytotoxic agents are well known and there are several
patients that have to postpone their treatment.[15, 16]
Apart from the side effects induced by the chemotherapeutic agents, there are several situations where
the tumor has infiltrated different parts of the airways
and respiratory distress is observed.[17] Several techniques can be used to open a closed central airway
and chemotherapy or radiotherapy can be used to
preserve the result.[18, 19] Debulking of cancer tissue
is usually performed with different types of lasers,
electrocautery, argon plasma coagulation (APC) or
cryotherapy.[20] (Figures 1-2) In order to keep the
airway opened we use additionally stent devices.[20,
21] Ballon dilatation and photodynamic therapy
(PDT) are other options with specific indications [22,
23] There is also a classification system for airway
stenosis that can be used by medical practitioners.[24]
Stents have been used for tracheal and esophageal
fistulas.[25, 26] For malignant airway stenosis we
usually use self-expanding covered or uncovered
stents. [21] In order to keep the good result of
debulking cancer tissue we have to choose carefully
the right time of debulking with systemic, intratumoral [27,149] (or a combination of both modalities
of) chemotherapy and / or radiotherapy. Moreover; it
has been observed that different stents (diameter,
length, materials) induce different local stress.[28]
Furthermore stents induce locally stress to the sur-
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rounding tissues. They increase proliferation of granuloma tissue in benign airway stenosis and increase
angiogenesis. Cancer tissue which already has increased angiogenesis when more stress is applied
locally shows further enhanced tissue formation.[29]
Therefore novel cytokine eluting stents are being developed.[30] Furthermore, novel research of stent
placement at least for the gastrointestinal tract has
indicated that stent placement might induce cancer
cell migration.[31] Several drugs have been used as
adjuvant local application in order to preserve the
airway passage.[30, 32-36] In this review we will focus
on the drugs that have been used with stents, their
pharmacological activity and future applications.
Additionally, we will include studies with data applicable for lung cancer patients.

Search strategy
We performed an electronic article search
through PubMed, Google Scholar, Medscape and
Scopus databases, using combinations of the following keywords: mitomycin c, floxuridine, sirolimus,
stents, lung cancer stents, dumon stents, zotarolimus,
rapamycin, 5-fluorouracil, doxycycline, everolimus
and pirfenidone. All types of articles (randomised
controlled trials, clinical observational cohort studies,
review articles, case reports) were included. Selected
references from identified articles were searched for
further consideration.

Figure 1. From top left to right bottom, hole made from excision of paratracheal tumor and covered stent placement with balloon dilation.

http://www.jcancer.org
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Figure 2. Argon plasma debulking.

Drug Pharmacology
Cisplatin
Cisplatin, is a well-known non-specific chemotherapy drug. It is one of the first member of a class of
platinum-containing anti-cancer drugs. These days
this group of drugs includes carboplatin, oxaliplatin
and lipoplatin. These platinum complexes react in
vivo, binding to and causing crosslinking of DNA,
which finally induce apoptosis. Cisplatin is usually
administered intravenously as short-term infusion in
normal saline for treatment. It is used to treat
(non-)small cell lung cancer, ovarian cancer, lymphomas, bladder cancer, cervical cancer, and germ
cell tumors.[37] Cisplatin has been observed to be
particularly effective against testicular cancer; the
cure rate was improved from 10% to 85%.[38]
Cisplatin is known to crosslink DNA in several
different ways, interfering with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis. Most notable
among the changes in DNA are the 1,2-intrastrand
cross-links with purine bases. These include
1,2-intrastrand d(GpG) adducts which form nearly
90% of the adducts and the less common
1,2-intrastrand d(ApG) adducts. 1,3-intrastrand
d(GpXpG) adducts occur but are readily excised by
the nucleotide excision repair (NER). Cisplatin has no
alkyl group unable to carry out alkylating reactions.
However;
it
is
correctly
classified
as
alkylating-like.[39, 40] Of note is the fact that different
chemotherapeutic especially alkylating agents (like
cyclophosphamide) play a specific role as causative
for initiation / aggravation of (underlying) pulmonary hypertension in cancer patients during specific
cancer treatment.[27] Such a (by chemotherapy) induced pulmonary hypertension is often classified as
pulmonary veno-occlusive disease (PVOD) which

resembles in many features a typical pulmonary arterial hypertension but is accompanied with a much
worse prognosis in comparison to e.g. an idiopathic
pulmonary arterial hypertension. Furthermore the
diagnosis of induced PVOD is even more difficult
when other hemodynamic comorbidities like left
heart disease is already existing on chemotherapy
initiation. It is worth mentioning that the establishment of the diagnosis of PVOD itself is very difficult
and many times only possible post-mortal. In regards
to real-life scenarios with underlying hemodynamic
relevant comorbidities it is one of the most complex
diagnosis in medicine in human beings alive. Therefore we believe that this diagnosis may be underscored in cancer patients and could be a part of the
explanation for the still worse prognosis in many solid
cancers especially under treatment despite new, very
expensive targeted therapies. It has to be mentioned
that any reduction of cardiac output will increase the
interstitial fluid pressure intratumorally which is
linked to a worse efficacy of any cancer treatment.

Cisplatin resistance
Cisplatin combination chemotherapy is the cornerstone treatment of many cancers. However; many
cancer patients will eventually relapse with cisplatin-resistant disease. Mechanisms regarding the cisplatin resistance have been proposed including
changes in cellular uptake and efflux of the drug, increased detoxification of the drug, inhibition of
apoptosis and increased DNA repair.[41, 42] Oxaliplatin is active in highly cisplatin-resistant cancer cells
in the laboratory but there is little evidence for its activity in the clinical treatment of patients with cisplatin-resistant cancer. The drug paclitaxel may be useful
in the treatment of cisplatin-resistant cancer; the
mechanism for this activity is yet unknown.[43] In
regards to hemodynamic properties of paclitaxel it is
http://www.jcancer.org
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of interest that this drug can influence the altitude of
life limiting pulmonary hypertension positively via
the Forkhead box O (FoxO) transcription factors
which are key regulators of cellular proliferation.
Using intravenous or inhaled paclitaxel will lead to
pharmacological
reconstitution
of
FoxO1
transcription factor activity in pulmonary artery
smooth muscle cells (PASMCs) which serves as a
potential
treatment
option
for
pulmonary
hypertension.[44] This detail my be of interest when
discussing chemotherapy options in cancer patients
with severe pulmonary hypertension beside cancer
diagnosis especially in the situation of no or minor
response to first line cisplatin.

Fluorouracil
Fluorouracil is a pyrimidine analog drug which
is used in the treatment of cancer. It is a suicide inhibitor and works through irreversible inhibition of
thymidylate synthase. This drug is an antimetabolite.
5-Fluorouracil acts primarily as a thymidylate synthase (TS) inhibitor. Its main action is to block the
synthesis of the pyrimidine thymidine which is a nucleoside required for DNA replication. Thymidylate
synthase methylates deoxyuridine monophosphate
(dUMP) in order to synthesize thymidine monophosphate (dTMP). The administration of 5-FU induces cell death via thymineless death.[45] Calcium
folinate stabilises the 5-FU-TS complex and enhances
5-FU's cytotoxicity.[46] There is very little difference
between the minimum effective dose and maximum
tolerated dose of 5-FU, and it has been observed that
the drug exhibits individual pharmacokinetic variability.[47-49] Therefore, an identical dose of 5-FU may
result in different therapeutic response between patients.[48] It has been observed that both overdosing
and underdosing are of concern with 5-FU. Moreover;
the majority of colorectal cancer patients treated with
5-FU are underdosed based on today's dosing standard, body surface area (BSA).[50-53] The limitations of
BSA-based dosing is an issue for many physicians as
they cannot accurately titer the dosage of 5-FU for the
majority of individual patients, which results in
sub-optimal treatment efficacy or excessive
toxicity.[51, 52]
The dihydropyrimidine dehydrogenase (DPD)
enzyme is responsible for the detoxifying metabolism
of fluoropyrimidines, a class of drugs that includes
5-fluorouracil, tegafur and capecitabine[54] Moreover;
genetic variations within the DPD gene (DPYD) can
lead to reduced or absent dihydropyrimidine dehydrogenase activity, and individuals who are heterozygous or homozygous for these variations may have
partial or complete DPD deficiency. It is estimated
that about 0.2% of individuals have complete dihy-
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dropyrimidine dehydrogenase deficiency.[54, 55]
Those patients with partial or complete dihydropyrimidine dehydrogenase deficiency have increased
risk of severe or even fatal drug toxicities when
treated with fluoropyrimidines; such as; neurotoxicity, myelosuppression.[55, 56]
At least two studies have found significant relationships between concentrations of 5-FU in blood
plasma and both desirable or undesirable effects on
patients. [52, 56] Further evaluation of the drug is
based on the concentration of 5-FU in plasma that can
increase desirable outcomes while minimizing negative side effects of 5-FU therapy.[52, 56] Towards this
direction a blood test has been created and is being
used in some centers as My5-FU test.[53]

Floxuridine
Floxuridine is an antimetabolite. The drug is
mostly used in the treatment of colorectal cancer.
Floxuridine, an analog of 5-fluorouracil, is a fluorinated pyrimidine.

Mitomycin C
The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. Mitomycin C (MTC, an antibiotic), finds use as a chemotherapeutic agent by virtue of its antitumour activity.
It is applied intravenously to treat upper gastro-intestinal cancers (e.g. esophageal carcinoma),
breast cancers and anal cancers, moreover; in bladder
instillation for superficial bladder tumours. It causes
delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged
use may result in permanent bone-marrow damage.
The usual adverse effects are lung fibrosis and renal
damage. Mitomycin C has also been used topically
rather than intravenously in several areas, like superficial cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single
instillation of this agent within 6 hours on bladder
tumor resection can prevent recurrence. Mitomycin C
is a potent DNA crosslinker. A single crosslink per
genome has shown to be effective in killing bacteria.
This is accomplished by reductive activation followed
by two N-alkylations. Both alkylations are sequence
specific for a guanine nucleoside in the sequence
5'-CpG-3'.[57] Potential bis-alkylating heterocylic
quinones were synthetised in order to explore their
antitumoral activities by bioreductive alkylation.[58]
Mitomycin is also used as a chemotherapeutic agent
in glaucoma surgery.[59] In the study by Li Y. et al.
[60] a novel combination of PEGylated phytosomes
with mitomycin C has been constructed in order to
enhance the efficacy of mitomycin C. PEG complex
http://www.jcancer.org
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has been observed in other studies that induces a
``stealth`` activity for several chemotherapeutic substances and in this way it produces a release effect for
many cytotoxic drugs.[61, 62] In the study by Moiseyenko VM. Et al. [63] it was observed that heavily
pretreated ovarian cancer patients carrying germ-line
BRCA1 mutation benefited from the administration of
mitomycin C. This study provides evidence that several molecular pathways of NSCLC should be investigated along with the local administration of mitomycin C (MTC). In regards to hemodynamic properties of this drug (especially in comparison to the above
mentioned details for cisplatin and paclitaxel) it is of
interest that MTC intravenous therapy is a potent
inducer of PVOD in humans and for intraperitoneal
MTC therapy in rats.[64] Amifostine prevents
MTC-induced PVOD in rats and should be tested as a
preventive therapy for MTC-induced PVOD in
humans.

Special Reference to
Pirfenidone
Pirfenidone is an anti-fibrotic drug which is
currently used in the treatment of idiopathic pulmonary fibrosis (IPF). It is known to reduce lung fibrosis
through downregulation of the production of growth
factors and procollagens I and II. Several studies have
established its antifibrotic and anti-inflammatory
properties in vitro systems and animal models of fibrosis.[65] A number of cell-based studies have
shown that pirfenidone reduces fibroblast proliferation,[66-69] inhibits tumor Growth Factor-β (TNF-β)
stimulated collagen production[70] and reduces the
production of fibrogenic mediators such as TGF-β.[68]
The drug has also shown to reduce production of inflammatory mediators such as tumor growth factor-α
(TNF-α) and interleukin 1β (IL-1β) in both cultured
cells and isolated human peripheral blood mononuclear cells.[71-74] These activities are consistent with
the broader antifibrotic and anti-inflammatory activities observed in animal models of fibrosis and in vitro.
[66, 69]

Everolimus
Everolimus is known to be a derivative of sirolimus and is considered an inhibitor of mammalian
target of rapamycin (mTOR). It is used as an immunosuppressant to prevent rejection of organ transplants and treatment of renal cell cancer and other
tumors. Much research has also been conducted on
everolimus and other mTOR inhibitors as a possible
targeted therapy for use in several types of cancers.
Like the others mTOR inhibitors its effect is solely on
the mTORC1 protein complex and not on the
mTORC2 complex. This function leads to a hy-
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per-activation of the kinase AKT via inhibition on the
mTORC1 negative feedback loop while not inhibiting
the mTORC2 positive feedback to AKT. This AKT
elevation can lead to longer survival in some cell
types. Based on this activity everolimus has an important effect on cell growth, cell proliferation and cell
survival. It has been observed that mTORC1 action is
modulated by several mitogens, growth factors and
nutrients.
The two genes TSC1 and TSC2 (which are the
genes involved in tuberous sclerosis disease) act as
tumour suppressor genes by regulating mTORC1
activity. Therefore the loss or inactivation of one of
these genes leads to the activation of mTORC1.[75]
Everolimus binds to its protein receptor FKBP12,
which directly interacts with mTORC1 inhibiting its
downstream signaling. As a consequence, mRNAs
that codify proteins implicated in the cell cycle inhibit
tumour growth.[75]
Recent trials have indicated that adding Afinitor
(everolimus) to exemestane therapy against advanced
breast cancer can significantly improve progression-free survival compared with exemestane therapy
alone.[76, 77] However, everolimus increased mortality in cancer patients in some studies.[77-79]
Furthermore, there are two studies that show a
different sensitivity to everolimus between patients
depending on their genome.[79, 80] In a Phase II clinical trial done in patients with advanced metastasic
bladder carcinoma (NCT00805129)[80] they found one
person that positively responded to everolimus
treatment for 26 months. A genetic sequence was
performed for this patient. It was discovered that
mutations in TSC1 lead to an increase in recurrence
and to an increase in the response time to everolimus.
Therefore, it has been determined that everolimus is
more efficient in those patients that present somatic
mutations in TSC1.[81]

Zotarolimus
Zotarolimus is an immunosuppressant and is
considered a semi-synthetic derivative of rapamycin.
It was primarily designed for use in stents with
phosphorylcholine as a carrier. It was observed that
coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. However, complications
have been observed with stent use, such as the development of thrombosis which impedes the efficiency of coronary stents. Moreover; haemorrhagic
and restenosis complications are additional problems
that can be observed. Therefore drug-eluting stents
have been developed. Stents are bound by a membrane consisting of polymers which releases zotarolimus slowly and its derivatives into the surrounding
http://www.jcancer.org
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tissues. Zotarolimus is an analog made by substituting a tetrazole ring in place of the native hydroxyl
group at position 42 in rapamycin. The compound is
extremely lipophilic, and therefore has limited water
solubility. The poor water solubility prevents rapid
release into the circulation (for coronary stents) since
elution of drug from the stent will be partly dissolution rate-limited. The slow rate of release and subsequent diffusion of the molecule facilitates the
maintenance of therapeutic drug levels eluting from
the stent. However; the surrounding tissue has to be
considered too. Moreover; its lipophilic property induces crossing cell membranes to inhibit neointimal
proliferation of target tissue. Zotarolimus is the most
lipophilic of all drug eluting stents (DES) drugs.[82]

Sirolimus
Sirolimus (also known as rapamycin) is a chemical that was discovered as a product of bacteria Sirolimus, was originally developed as an antifungal
agent. However, this use was abandoned when it was
discovered to have potent immunosuppressive and
antiproliferative properties. It has been shown to
prolong the life of mice and might also be useful in the
treatment of certain cancers. [83] Sirolimus is not a
calcineurin inhibitor, but it has a similar suppressive
effect on the immune system. Sirolimus inhibits interleukin-2 (IL-2) and other cytokines receptor-dependent signal transduction mechanisms, via
action on mTOR, and thereby blocks the activation of
T and B cells. It is known that tacrolimus and cyclosporine inhibit the secretion of IL-2, by inhibiting calcineurin. Sirolimus binds to the cytosolic protein
FK-binding protein 12 (FKBP12) like tacrolimus. Unlike the tacrolimus-FKBP12 complex, which inhibits
calcineurin (PP2B), the sirolimus-FKBP12 complex
inhibits the mTOR (mechanistic (formerly mammalian) target of Rapamycin. Rapamycin directly binds to
mTOR Complex 1 (mTORC1). mTOR has also been
called FRAP (FKBP-rapamycin-associated protein),
RAPT1, RAFT (rapamycin and FKBP target). Sirolimus binds to FKBP12-sirolimus complex and inhibits
Tor1 and Tor2. [84-86] There have been numerous
studies with sirolimus-eluting stents used for coronary disease.[87-91]. Sirolimus eluting stents have
demonstrated that they can inhibit neointimal proliferation when applied next to bare metal stents.[87, 92,
93] Several groups have investigated different combinations of sirolimus and sustain release drugs in
order to prolong the positive effect of the stent.[88, 89,
94, 95] Several imaging methods have been also applied in order to evaluate sirolimus stent implantation
in the coronary vessels. [91, 96, 97]In the study by
Habib et. al. [98] it was observed that metformin impairs vascular endothelial recovery after stent place-
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ment in the setting of locally eluted mammalian target
of rapamycin inhibitors. Metformin could therefore be
administered as an adjuvant treatment for these patients or added in the eluting solution. The administration of granulocyte colony-stimulating factor has
been observed to attenuate endothelial dysfunction
after sirolimus eluting stent implantation.[99] In the
study by Erdim et. al. [100] and Tarantini et. al. [101]
there were a difference observed between paclitaxel
eluting stents and sirolimus eluting stents. The same
was true when sirolimus and paclitaxel eluting stents
were compared to bare metal stents.[102]

Paclitaxel
Paclitaxel is used to treat a number of cancers
such as; ovarian cancer, breast cancer, lung cancer and
pancreatic cancer. Paclitaxel and docetaxel represent
the taxane family of drugs. Paclitaxel's mechanism of
action involves interference with the normal breakdown of microtubules during cell division. Its common side effects include: muscle and joint pains, hair
loss, and diarrhea. Anaemia and infections can occur
and can be potentially serious. It should not be used
during pregnancy as it often results in problems in the
infant. Paclitaxel is used as an antiproliferative agent
for the prevention of restenosis (recurrent narrowing)
of coronary and peripheral stents; locally delivered to
the artery wall. It has been observed that paclitaxel
coating limits the growth of neointima (scar tissue)
within stents.[103] It is known that paclitaxel targets
tubulin. Paclitaxel-treated cells have defects in mitotic
spindle assembly, chromosome segregation, and cell
division. Paclitaxel stabilizes the microtubule polymer
and protects it from disassembly. Consequently
chromosomes are unable to achieve a metaphase
spindle configuration. This function blocks progression of mitosis, and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the
G-phase of the cell cycle without cell division. It has
been observed that the ability of paclitaxel to inhibit
spindle function is generally attributed to its suppression of microtubule dynamics. Moreover; in vitro
studies it has been observed that at higher therapeutic
concentrations, paclitaxel appears to suppress microtubule detachment from centrosomes. This process
occurs during mitosis. Paclitaxel binds to beta-tubulin
subunits of microtubules.[104-108] Paclitaxel eluting
stents have been used for airway bypass [109] and for
coronary vessel implantation.[100-102, 110-114]
Paclitaxel solution has been also conjugated with a
carrier in order to produce a sustain drug release effect.[115]

Doxycline
Doxycycline is a broad-spectrum antibiotic of the
http://www.jcancer.org
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tetracycline class that is useful for the treatment of
many infections. Doxycycline–metal ion complexes
are unstable at acid pH, therefore more doxycycline
enters the duodenum for absorption while other earlier tetracycline compounds are released in the upper
gastrointestinal tract. Moreover; it was mentioned
that food has less effect on absorption than on absorption of earlier drugs with doxycycline serum
concentrations being reduced by about 20% by test
meals compared with 50% for tetracycline.[116] Expired tetracyclines or tetracyclines allowed to stand at
a pH less than 2 are reported to be nephrotoxic due to
the formation of a degradation product, such as the
hydro-4-epitetracycline which induces the Fanconi
syndrome. It is known for doxycycline that the absence of a hydroxyl group in C-6 prevents the formation of this nephrotoxic compound. Tetracyclines
and doxycycline itself have to be taken with precaution by patients with kidney injury, as they can
worsen azotemia due to catabolic effects.[117] In the
study by Huvenne W. et. al. [36] it was observed that
doxycycline-releasing stents improved postoperative
healing after functional endoscopic sinus surgery.

Sirolimus vs. Everolimus
In the study by Gao R. et. al. [94] novel abluminal
groove-filled biodegradable polymer sirolimus eluting stent was investigated versus a durable polymer
everolimus-eluting stent: None of the two stents presented positive results after 12 months follow up and
none was observed to be superior. Regarding the
novel abluminal groove-filled biodegradable polymer
sirolimus eluting stent the authors stated that the stent
was not inferior to the everolimus stent. The stents
were found to be effective mainly for the first nine
months. In the study by Smits P. C. et. al. [118] abluminal biodegradable polymer biolimus-eluting stents
were tested versus durable polymer everolimus
stents: This time the biolimus stents were found to be
as effective as the everolimus stents. In the study by
Harjai K. J. et. al. [110] it was observed that everolimus eluting stents were more efficient when compared to sirolimus and paclitaxel eluting stents at least
for 3 months of follow up. Again in the study by Park
K. W. et. al. [119] Kitabata H. et. al. [120], Moreno R.
et. al. [121], Kozuma K. et. al. [122] and Ko Y-G. et. al.
[97] everolimus eluting stents were found to be superior when compared to sirolimus eluting stents.

Zotarolimus vs. Everolimus
In the study by Tandjung K. et. al. [123] no difference was observed between the zotarolimus and
everolimus stents in terms of safety and efficiency.
However; in the study by Kim S. et. al. [124] although
zotarolimus had rapid neointimal healing at 3
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months, the zotarolimus stents had a slightly better
vascular healing profile at long term 12 months. In the
study by Park K. W. et. al. [125] both zotarolimus and
everolimus stents showed the same safety and efficiency profile after 1 year follow-up.

Zotarolimus vs. Paclitaxel
In the study by Xu B. et. al. [126] It was observed
that zotarolimus stents were more efficient when
compared to paclitaxel eluting stents within 12
months of follow up.

Sirolimus vs. Zotarolimus
In the study by Van den Branden B. et. al. [127]
sirolimus eluting stents were found to have higher
efficiency than zotarolimus stents.

Stent Studies for the respiratory tract
Cisplatin
In the study by Chao YK et al. [35] biodegradable
stents made of polycaprolactone were fabricated by a
laboratory-made, microinjection molding machine.
Initially, in vitro mechanical strength of the stents was
compared with the strength of Ultraflex SEMSs. Polylactide-polyglycolide copolymer and cisplatin were
coated onto the surfaces of the stents. Elution method
and high-performance liquid chromatography
(HPLC) analysis were used to examine the in vitro
cisplatin release characteristics. In vivo, the stents
were surgically implanted into the cervical trachea of
white rabbits. Bronchoscopic examination was performed weekly and Cisplatin concentrations in trachea, lung, and blood were analyzed by HPLC. Histologic examination was also performed. The biodegradable stent exhibited mechanical strength comparable to the strength of Ultraflex SEMSs and provided
a steady release of cisplatin for 4 weeks in vitro. The in
vivo study showed sustained cisplatin levels in rabbit
trachea for 5 weeks with a minimum drug level in
blood. Histologic examination showed an intact ciliated epithelium and marked leukocyte infiltration in
the submucosa of the stented area.

Mitomycin C
In the study by Choomg C. K. et al. [128] mitomycin C (MTC) was administered locally after stent
placement for airway bypass and blocked granuloma
tissue formation for up to a week. In the study by
Coppit G. et. al. [129] MTC failed to affect the acute
inflammatory response, perhaps secondary to the
robust inflammatory reaction created by combining a
single-stage laryngotracheal reconstruction (SSLTR)
with the local circumferential trauma induced by the
Palmaz stent. This may have reduced the beneficial
effects of the MTC in this study. However; incorporahttp://www.jcancer.org
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tion of the auricular cartilage graft the stent was improved, contributing again to improved airway stability. The mechanism of this action is not yet understood, as MTC is considered a potent fibroblast inhibitor and not a promoter of neochondrogenesis. It is
possible that this is an effect of MTC not previously
described. In the study by Sztano B. et. al. [130] mitomycin C prolonged fibrotic tissue formation for almost 6 weeks in a young boy. On the other hand in the
study by Uzomefuna V. et. al. [131] again it did not
present a positive antiproliferative effect, however;
the authors provide data where the effect might be
associated with the patients’ age. In the study by
Carter J. M. et. al. [132] the positive application of
MTC was observed with fewer days of hospitalization. In another study by Kim H. et. al. [133] investigating again the effect of MTC application in congenital choanal atresia as in the study by Carter J. M. et.
al. [132] no positive effect was observed in this group.
In the study by Cardoso P.F.G. et.al. [109] paclitaxel
eluting stents were used for airway bypass. Initial
results indicated reduction of hyperinflation and improved pulmonary function and dyspnea. In the
study by Choong C.K. et. al. [134] in an animal model
prolongation of patency was observed. However; in
the study by Shah P.L. et. al. [135] no benefit was observed from these stents for homogenous emphysema. Although a previous study by the same group
implicated that these patients might benefit from
these stents.[136] In the study by Zhu G. H. et. al. [137]
bioabsorbable tubular stents eluting MTC (tracheal)
were created and they were found to be superior to
silicone stents. This study is very important because it
provides data regarding the importance of the stent
design in mucus trapping. The authors propose a
stent design along with a drug eluting carrier, however; further investigation is needed for the stent design.

Doxycycline
In the study by Huvenne W. et. al. [36] doxycycline drug eluting stents were designed and applied
for sinus surgery. It was observed that matrix metalloproteinase-(MMP-9) levels were lower along with
bacterial colonization and additionally short time
healing was observed.

Carriers designed for coronary, airway
and gastrointestinal stents
In the study by Bang S. et. al. [138] paclitaxel-eluting membranes were designed in order to release paclitaxel: Positive results have been observed
for more than 15 days after implantation. In the study
by Qiu H. et. al. [88] sirolimus bioabsorable
poly-L-lactic acid stents were designed and were ef-
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fective up to 28 days. In the study by Deng J. et. al.
[89] a nanoporous CREG-sirolimus eluting stent was
designed with positive effects between 2-4 weeks. In
the study by Christiansen E. H. et. al. [139] a biolimus-eluting biodegradable polymer-coated stent was
compared to durable polymer-coated sirolimus-eluting stent, however; after 1 year the results
did not indicate a superiority of these novel stents. In
the study by Gao R. et. al. [94] novel abluminal
groove-filled biodegradable polymer sirolimus eluting stent was investigated versus a durable polymer
everolimus-eluting stent: None of the two stents presented positive results after 12 months follow up and
none was observed to be superior from one another.
In the study by Huvenne W. et. al. [36] a doxycycline
eluting stent was created from copolymer blocks. It
was observed that matrix metalloproteinase-(MMP-9)
levels were lower along with bacterial colonization
and additionally short time healing was observed. In
the study by Chao Y. et. al. [35] polylactide-polyglycolide copolymer-cisplatin stents were
designed and a sustainable release was observed for
up to 5 weeks. In the study by Lemos P. et. al. [140]
using polymer-free phospholipid encapsulated sirolimus nanocarriers stents the drug transfer was feasible to all layers of the vessel wall, achieving high tissue concentration that persisted days after the application. In the study by Seo J-B. et. al. [113] two different types of paclitaxel eluting stents were investigated: The polymer polysulfone (Coroflex) and polymer ``Translute`` (Taxus). The Taxus stent was observed to be superior to the Coroflex within a 9 month
follow up.

Discussion
The inherent growth inhibitory properties of
many anti-cancer agents make these drugs ideal candidates for the prevention of restenosis. However,
these same properties are often associated with local
cytotoxicity such as; fistulas. Therefore a multimodality approach is necessary either with debulking and
then stent placement or radiotherapy when appropriate. Performance status, comorbidities, disease
extend and anatomical malformations of the patient
should be considered.
Preparation is necessary in many cases as airway
malformation is observed and therefore 3 dimensional
investigation has been proposed.[141] In the study by
Ratnovsky A. et. al. [28] the stress of different materials were investigated and the authors proposed a patient-specific trachea model evaluation before stenting
the patient. The method of stent application/stress,
different material and different tissue (benign/malignant) could probably be assessed one day
for each patient before application in order to avoid
http://www.jcancer.org
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adverse effects. Since MTC is an antitumour drug that
is used in both benign and malignant tissue formation
after stent placement, we suggest that other cytotoxic
agents with or without carrier that modulate the release of the drug locally should be investigated.[57]
Regarding pirfenidone, we cannot propose further
studies when we have tissue formation around the
edge of a stent if the underlying disease is cancer,
however; it would be interesting to design
pirfenidone eluting stents for benign obstructions. In
the study by Barone-Rochette G. et. al. [142] data are
presented where current technology of drug eluting
stents is cost effective and therefore novel stents
should be encouraged. An issue to be investigated is
whether we should provide the patients with an adjuvant therapy when implanting an airway stent.
There is the case of the immunosuppressant rapamycin which was the basis for the development of zotarolimus by Johnson and Johnson. Rapamycin was
originally approved for the prevention of renal transplant rejection in 1999. There is evidence for coronary
stents that when metformin is administered impairment of vascular endothelial recovery is observed.
More studies should be performed towards this direction. Another issue is the adverse effects of the
drugs that are conjugated with the stent. There is a
case reported where a zotarolimus eluting stent induced hypersensitivity pneumonitis.[143] In the study
by Iwata Y. et. al. [99] granulocyte colony-stimulating
factor was administered and it was observed that
endothelial dysfunction was attenuated after sirolimus eluting stents implantation. Again in the study
by Rhew S. H. et. al. [144] repeated catastrophic multi-vessel coronary spam was observed after zotarolimus-eluting stent. In the study by Zhu G. H. et. al.
[137] bioabsorbable tubular tracheal stents eluting
MTC were created and found to be superior to silicone stents. This study is very important because it
provides data regarding the importance of the stent
design in mucus trapping. The authors propose a

stent design along with a drug eluting carrier, however; further investigation is needed for the stent design. 5- fluorouracil (5-FU) nitinol stents have been
used for the gastrointestinal tract, and could be investigated for the respiratory tract.[145] There are currently novel methods for evaluating the concentration
of paclitaxel and 5-FU simultaneously [146], moreover; novel ampiphilic copolymers have been designed
to control the drug release such as; 5-FU.[146-148]
(Figure 3, Tables 1-2)
In our mini review we investigate the current
knowledge from the coronary drug eluting stents and
we present also a comparison between the different
materials. We are trying to create a bridge between
this knowledge and the data that we obtained from
eluting airway stent techniques. There has not been
much effort towards stents for lung cancer patients.
The main reason is that patients usually have a low
performance status when stents are applied usually as
palliative treatment. Moreover; interventional pulmonology has many tools for rapid local control.
However; a long term local therapy through airway
stents for these patients is welcomed. Going through
the literature we believe that an ideal airway stent
should (1) possess sufficient strength to perform its
mechanical function, (2) be biocompatible so that the
material breakdown process will not cause any tissue
irritation, (3) be biodegradable (no need for removal
after serving its purpose), and/or (4) provide effective
pharmaceuticals for a sustained period of time. Before
stent placement we propose investigation of the airways with computertomography scans and bronchoscopy in order to choose the best stent design and
make the appropriate intervention. Finally, the type of
lung cancer should direct us to choose the appropriate
drug in order to invent drug eluting stents. Agents
effective against specific types of lung cancers have
been found, such as permetrexed for adenocarcinoma
or TKIs for EGFR or ALK positive patients.

Table 1. Stent studies (In the result section the referenced time indicates the time where the first positive results were observed.)
Author
Chao Y.K. et. Al.
Choong C.K. et al.
Coppit G. et. al.
Sztano B.et. al.
Uzomefuna V. et. al.
Carter J. M. et. al.
Kim H. et. al.
Cardoso F.G.P. et. al.
Choong C. K. et. al.
Shah P.L.et. al.
Huvenne W. et. al.

Subject
animals
animals
animals
human
human
human
human
human
animal
human
human

Drug
Cisplatin with carrier
Mitomycin C
Mitomycin C
Mitomycin C
Mitomycin C
Mitomycin C
Mitomycin C
Paclitaxel
Paclitaxel
Paclitaxel
Doxycycline

Result
5 week with apoptosis
1 week
No effect
6 weeks
No effect
Less hospitilisation days
No effect
Positive effect (emphysema application)
Prolongation of patency
No benefit, however; safe
Shorter healing time, less bacterial colonization, lower MMP-9 levels

Ref
35
129
130
131
132
133
134
110
135
136
36
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Table 2. Carriers designed for coronary and airway stents.
-Paclitaxel eluting stents
-Sirolimus bioabsorable poly-L-lactic acid
-Nanoporous CREGES (Sirolimus)
-Biolimus-eluting biodegradable polymer-coated stent
-Novel abluminal groove-filled biodegradable polymer sirolimus eluting stent
-Doxycycline eluting stent was created from copolymer blocks
-Polylactide-polyglycolide copolymer-cisplatin
-Polymer-free phospholipid encapsulated sirolimus nanocarriers
-Bioabsorbable tubular stents
-Amphiphilic poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) (PCL-PEG-PCL) copolymers
- trilayered Poly(ε-caprolactone) (PCL)-based film with a coating layer (CL), a drug-storing layer (DSL)

Figure 3. Drug eluting stents algorithm.
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